B-CELL MALIGNANCIES

This trial is testing a new combination of engineered immune cell therapies for people with hard-to-treat B-cell cancers. It aims to improve treatment and prevent cancer from coming back by using cells that target up to seven different markers on cancer cells at once. The study w…

This study is testing a new drug called AZD5492 for adults whose B-cell cancers have come back or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. The drug works by directing the patient's own immune T…

This study is testing whether adding a new drug called emavusertib to an existing cancer medication (zanubrutinib) can better control chronic lymphocytic leukemia and similar blood cancers. It will enroll 108 adults who are already taking zanubrutinib but need additional treatmen…

This study is testing a new type of personalized cell therapy called CD22 CAR-T for patients whose B-cell blood cancers have come back or not responded to other treatments, including other CAR-T therapies. Doctors will collect a patient's own immune cells, genetically modify them…

This early-stage study is testing a new type of drug that uses mRNA technology, similar to some COVID-19 vaccines, to treat B-cell blood cancers like leukemia and lymphoma that have not responded to standard treatments. The drug is designed to target a protein called CD19 found o…

This is the first study in people testing an experimental oral drug called ABBV-525 for several types of advanced B-cell blood cancers, including lymphoma and leukemia. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it …

This trial is testing a new, fourth-generation version of CAR-T cell therapy for patients whose B-cell cancers have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better hunt and destroy cancer cells, and includes…